Literature DB >> 35134850

Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.

Jimmy Ma1, Robin M Nance1, Joseph A C Delaney2, Bridget M Whitney1, Laura Bamford3, Ronnie M Gravett4, Richard D Moore5, Sonia Napravnik6, Kenneth H Mayer7, Jeffrey M Jacobson8, Katerina Christopoulos9, Greer A Burkholder4, Jeanne Keruly5, Joseph J Eron6, Jeffrey Martin10, Edward R Cachay3, Michael S Saag4, Heidi M Crane1, Mari M Kitahata1.   

Abstract

Among 14 049 people with human immunodeficiency virus in care in 2019-2020, 96% were treated with antiretroviral therapy (ART). Current antiretroviral treatment patterns highlight high uptake of guideline-recommended ART regimens including second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) and tenofovir alafenamide, especially in antiretroviral-naive individuals initiating ART.
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ART guidelines; ART treatment trends; ART utilization; integrase inhibitor; tenofovir alafenamide

Mesh：

Substances：

Year:  2022        PMID： 35134850      PMCID： PMC9464068          DOI： 10.1093/cid/ciac086

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   20.999


  9 in total

1.  Antiretroviral prescribing patterns in treatment-naïve patients in the United States.

Authors:  James A McKinnell; James H Willig; Andrew O Westfall; Christa Nevin; Jeroan J Allison; James L Raper; Michael J Mugavero; Michael S Saag
Journal:  AIDS Patient Care STDS       Date:  2010-02       Impact factor: 5.078

2.  Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Authors:  Pedro Cahn; Juan Sierra Madero; José Ramón Arribas; Andrea Antinori; Roberto Ortiz; Amanda E Clarke; Chien-Ching Hung; Jürgen K Rockstroh; Pierre-Marie Girard; Jörg Sievers; Choy Man; Alexander Currie; Mark Underwood; Allan R Tenorio; Keith Pappa; Brian Wynne; Anna Fettiplace; Martin Gartland; Michael Aboud; Kimberly Smith
Journal:  Lancet       Date:  2018-11-09       Impact factor: 79.321

3.  Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Authors:  Paul E Sax; David Wohl; Michael T Yin; Frank Post; Edwin DeJesus; Michael Saag; Anton Pozniak; Melanie Thompson; Daniel Podzamczer; Jean Michel Molina; Shinichi Oka; Ellen Koenig; Benoit Trottier; Jaime Andrade-Villanueva; Gordon Crofoot; Joseph M Custodio; Andrew Plummer; Lijie Zhong; Huyen Cao; Hal Martin; Christian Callebaut; Andrew K Cheng; Marshall W Fordyce; Scott McCallister
Journal:  Lancet       Date:  2015-04-15       Impact factor: 79.321

4.  Changes in HIV antiretroviral prescribing practices in the United States.

Authors:  Quan M Vu; R Luke Shouse; Kathleen Brady; John T Brooks; John Weiser
Journal:  Int J STD AIDS       Date:  2019-12-02       Impact factor: 1.359

5.  Antiretroviral treatment among commercially insured persons living with HIV in an era of universal treatment in the United States - 2012-2014.

Authors:  Kashif Iqbal; Ya-Lin A Huang; Philip Peters; Paul Weidle; Karen Hoover
Journal:  AIDS Care       Date:  2018-06-20

6.  U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.

Authors:  Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks
Journal:  Ann Intern Med       Date:  2012-09-04       Impact factor: 25.391

7.  Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems.

Authors:  Mari M Kitahata; Benigno Rodriguez; Richard Haubrich; Stephen Boswell; W Christopher Mathews; Michael M Lederman; William B Lober; Stephen E Van Rompaey; Heidi M Crane; Richard D Moore; Michael Bertram; James O Kahn; Michael S Saag
Journal:  Int J Epidemiol       Date:  2008-02-08       Impact factor: 7.196

8.  Clinician Perspectives on Delaying Initiation of Antiretroviral Therapy for Clinically Eligible HIV-Infected Patients.

Authors:  Linda Beer; Eduardo E Valverde; Jerris L Raiford; John Weiser; Becky L White; Jacek Skarbinski
Journal:  J Int Assoc Provid AIDS Care       Date:  2014-11-12

9.  Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options.

Authors:  Kristina L Bajema; Robin M Nance; Joseph A C Delaney; Ellen Eaton; Thibaut Davy-Mendez; Maile Y Karris; Richard D Moore; Joseph J Eron; Benigno Rodriguez; Kenneth H Mayer; Elvin Geng; Cindy Garris; Michael S Saag; Heidi M Crane; Mari M Kitahata
Journal:  AIDS       Date:  2020-11-15       Impact factor: 4.632
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.